A recent study sponsored by the FDA in 2011 specifically addresses NuvaRing® and finds that its users are at an increased risk of suffering a blood clot when compared to users of second generation low estrogen oral contraceptives. We anticipate that further studies will begin to emerge regarding the increased risks of NuvaRing® and etonogestrel.
NuvaRing® was approved by the FDA on October 3, 2001, and began distribution in 2002. In marketing NuvaRing® its manufacturers represented that NuvaRing® was the first and only once-a-month vaginal birth control ring, but with the same efficacy as daily birth control pills. However, the manufacturers of NuvaRing® inadequately tested NuvaRing® and failed to discover increased safety risks associated with its use.
NuvaRing® is a combination contraceptive vaginal ring that contains two active ingredients: etonogestrel and ethinyl estradiol. Etonogestrel is the active metabolite of desogestrel, which is classified as a third generation progestin. Studies concerning oral contraceptives that contain desogestrel and other third generation progestins report an increased risk of venous thromboembolism compared to second generation products. In its product label, however, the manufacturer of NuvaRing® states that it is unknown whether NuvaRing® increases the risk of venous thromboembolism.
Burg Simpson has a national reputation as a being a leader for plaintiffs and victims in personal injury litigation against large pharmaceutical companies. Therefore, if you or a loved one has used NuvaRing® and suffered from any of the following injuries, please call us today for a free case evaluation:
- Deep vein thrombosis (blood clot in a deep vein)
- Pulmonary embolism (blood clot in the lung)
- Heart attack